US equities
|
SPCX
$166.83
▲+4.95%
NVDA
$236.92
▲+1.27%
MU
$1,064.33
▼-0.98%
TSLA
$377.57
▲+1.88%
MSFT
$526.42
▲+1.72%
SNDK
$1,714.09
▼-0.34%
INTC
$117.26
▼-1.73%
META
$745.36
▲+2.37%
SPCX
$166.83
▲+4.95%
NVDA
$236.92
▲+1.27%
MU
$1,064.33
▼-0.98%
TSLA
$377.57
▲+1.88%
MSFT
$526.42
▲+1.72%
SNDK
$1,714.09
▼-0.34%
INTC
$117.26
▼-1.73%
META
$745.36
▲+2.37%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Soligenix, Inc. - Common Stock
(NQ:
SNGX
)
0.3627
-0.0027 (-0.74%)
Delayed Quote
Updated: 11:43 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Soligenix, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) CEO Highlights Capital Discipline as Critical to Biotech Success in Pharmaphorum Analysis
April 21, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach
April 20, 2026
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status
April 17, 2026
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results
April 16, 2026
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Gains Analytical Validation as Pipeline Progress Drives Forward Outlook
April 15, 2026
Via
Investor Brand Network
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Showcased for Smarter Path to Drug Development
April 14, 2026
Via
Investor Brand Network
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
April 10, 2026
Via
ACCESS Newswire
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy
April 02, 2026
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Advances Clinical Credibility with HyBryte Research Publication
April 01, 2026
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Expands Pipeline Momentum as SGX945 Earns Global Recognition
March 31, 2026
Via
Investor Brand Network
BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results
March 31, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease
March 26, 2026
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach
March 24, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Advances Orphan Drug Strategy With HyBryte In Rare Skin Cancer
March 23, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
March 23, 2026
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation
March 20, 2026
Via
Investor Brand Network
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Highlights HyBryte Clinical Data In Peer-Reviewed Journal Publication
March 19, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Featured On BioMedWire Podcast Highlighting Phase 3 HyBryte Progress And Key Inflection Points
March 19, 2026
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Innovation Through Platform Science and Expanding Therapeutic Pipeline
March 18, 2026
Via
Investor Brand Network
BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behçet Disease
March 10, 2026
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Secures Key European Milestone for Dusquetide Development
March 09, 2026
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach
March 05, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Receives Positive EMA Orphan Drug Opinion for Dusquetide in Behçet Disease
February 26, 2026
Via
Investor Brand Network
BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) CEO to Present at BIO Investment & Growth Summit
February 24, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) CEO Highlights 2026 Clinical Milestones and Strategic Options
February 12, 2026
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Driving Innovation in Photodynamic Therapy Potential in Oncology, Dermatology
February 10, 2026
Via
Investor Brand Network
NetworkNewsBreaks – Soligenix Inc.’s (NASDAQ: SNGX) SGX945 Shows Promise with Immune-Modulating Approach
February 06, 2026
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Builds Momentum in Fight Against Rare, Chronic Cancer
February 02, 2026
Via
Investor Brand Network
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
January 30, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Targets Critical Gaps in CTCL Treatment with HyBryte(TM)
January 29, 2026
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
Next >
